Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 12/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394982 | 0.79 | PTGDR2 (0.44) | DDR1HTR2ASLC6A4KCNH2CCR2 | |
| SCHEMBL2395866 | 0.78 | CCR2 (0.41) | DDR1HTR2ASLC6A4KCNH2CCR2 | |
| SCHEMBL4638347 | 0.76 | AR (0.41) | DDR1HTR2ASLC6A4KCNH2CCR2 | |
| SCHEMBL2394992 | 0.76 | HTR2A (0.45) | HTR2ASLC6A4KCNH2MAPTAR | |
| SCHEMBL3924227 | 0.75 | HTR2A (0.46) | HTR2ASLC6A4KCNH2CCR2RHEB | |
| SCHEMBL3924231 | 0.74 | AR (0.46) | HTR2ASLC6A4KCNH2CCR2RHEB | |
| SCHEMBL2065615 | 0.71 | PTGDR2 (0.47) | DDR1RHEBPTGDR2 | |
| SCHEMBL1331610 | 0.70 | PTGDR2 (0.51) | PTGDR2PPARG | |
| SCHEMBL15358107 | 0.69 | DDR1 (0.46) | DDR1CCR2 | |
| SCHEMBL27993340 | 0.69 | TSHR (0.45) | DDR1CCR2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| CN-102557971-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-07-11 | — | — | CN | disclosed |
| CN-101014564-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-05-09 | — | — | CN | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | DDR1 4028/4885HTR2A 298/4885SLC6A4 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.